chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Eye pain, Fatigue, Headache, Lymphadenopathy, Muscle twitching
Clinical narrative: Sore right arm, increased stiffness in neck and shoulders, intermittent headache, right hand tingling (thumbs and fingers) and slight swelling of thumb and last 2 fingers on right hand, right thumb pain at base, right side stomach pain moving to just below center rib cage, left thumb pain at base, pain over left eye, fatigue, sneezing, dry eyes, swelling of left and right arm pit lymph nodes, fever in the evening of 6/1 and 6/2, sinus congestion, off and on sharp cramping in right knee the evening of 6/1, two lumps on right arm above elbow by 6/2 morning (became rashy, swollen and hot/itchy, looked like sunburn), left breast tenderness, back and leg aches. noticed muscle twitch above right elbow on 6/4. Took
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal chest pain, Musculoskeletal stiffness, Pain in extremity, Paraesthesia, Peripheral swelling
Clinical narrative: Sore right arm, increased stiffness in neck and shoulders, intermittent headache, right hand tingling (thumbs and fingers) and slight swelling of thumb and last 2 fingers on right hand, right thumb pain at base, right side stomach pain moving to just below center rib cage, left thumb pain at base, pain over left eye, fatigue, sneezing, dry eyes, swelling of left and right arm pit lymph nodes, fever in the evening of 6/1 and 6/2, sinus congestion, off and on sharp cramping in right knee the evening of 6/1, two lumps on right arm above elbow by 6/2 morning (became rashy, swollen and hot/itchy, looked like sunburn), left breast tenderness, back and leg aches. noticed muscle twitch above right elbow on 6/4. Took
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Pyrexia, Rash, Sinus congestion, Skin warm
Clinical narrative: Sore right arm, increased stiffness in neck and shoulders, intermittent headache, right hand tingling (thumbs and fingers) and slight swelling of thumb and last 2 fingers on right hand, right thumb pain at base, right side stomach pain moving to just below center rib cage, left thumb pain at base, pain over left eye, fatigue, sneezing, dry eyes, swelling of left and right arm pit lymph nodes, fever in the evening of 6/1 and 6/2, sinus congestion, off and on sharp cramping in right knee the evening of 6/1, two lumps on right arm above elbow by 6/2 morning (became rashy, swollen and hot/itchy, looked like sunburn), left breast tenderness, back and leg aches. noticed muscle twitch above right elbow on 6/4. Took
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Sneezing, Swelling
Clinical narrative: Sore right arm, increased stiffness in neck and shoulders, intermittent headache, right hand tingling (thumbs and fingers) and slight swelling of thumb and last 2 fingers on right hand, right thumb pain at base, right side stomach pain moving to just below center rib cage, left thumb pain at base, pain over left eye, fatigue, sneezing, dry eyes, swelling of left and right arm pit lymph nodes, fever in the evening of 6/1 and 6/2, sinus congestion, off and on sharp cramping in right knee the evening of 6/1, two lumps on right arm above elbow by 6/2 morning (became rashy, swollen and hot/itchy, looked like sunburn), left breast tenderness, back and leg aches. noticed muscle twitch above right elbow on 6/4. Took
Age: 85.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, COVID-19 pneumonia, SARS-CoV-2 test positive
Clinical narrative: Patient received Moderna COVID vaccine on 1/23/21 (lot # 042L20A), 2/23/21 (lot # 002A21A), 11/24/21 (lot # 065F21A). On 6/2/22, patient admitted to our inpatient facility (med/surg unit) with acute respiratory failure with hypoxia and COVID19 pneumonia. Patient was discharged home earlier today on 6/6/22.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: urticaria (hives)
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain, Pyrexia
Clinical narrative: The next day I have fever, body aches and fatigue. All went away but the fatigue.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: No adverse reaction.  Vaccine temperature excursion.  Vaccine was kept at a frozen temperature, not refrigerated temperature upon receipt of shipment.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: No adverse reaction.  Vaccine temperature excursion.  Vaccine was kept at a frozen temperature, not refrigerated temperature upon receipt of shipment.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Condition aggravated, Dizziness, Dry skin
Clinical narrative: Severe Chills. Arthralgia. Severe muscle aches - all extremities and lumbar and cervical. 6/3 ( about 10days post injection)  Awoke with very severe vertigo and dizziness.  Severe nausea and vomiting and retching and migraine and chills and severe fatigue.- Lasting 12 hours.   Treated with compazine and zofran po and imetrex.    Left arm ache for 3 days post injection and couple days with severe fatigue, headaches.  Remain intermittent itching of extremities with cracked dry skin hands.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Migraine, Myalgia, Nausea
Clinical narrative: Severe Chills. Arthralgia. Severe muscle aches - all extremities and lumbar and cervical. 6/3 ( about 10days post injection)  Awoke with very severe vertigo and dizziness.  Severe nausea and vomiting and retching and migraine and chills and severe fatigue.- Lasting 12 hours.   Treated with compazine and zofran po and imetrex.    Left arm ache for 3 days post injection and couple days with severe fatigue, headaches.  Remain intermittent itching of extremities with cracked dry skin hands.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pruritus, Retching, Skin fissures, Vertigo
Clinical narrative: Severe Chills. Arthralgia. Severe muscle aches - all extremities and lumbar and cervical. 6/3 ( about 10days post injection)  Awoke with very severe vertigo and dizziness.  Severe nausea and vomiting and retching and migraine and chills and severe fatigue.- Lasting 12 hours.   Treated with compazine and zofran po and imetrex.    Left arm ache for 3 days post injection and couple days with severe fatigue, headaches.  Remain intermittent itching of extremities with cracked dry skin hands.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Severe Chills. Arthralgia. Severe muscle aches - all extremities and lumbar and cervical. 6/3 ( about 10days post injection)  Awoke with very severe vertigo and dizziness.  Severe nausea and vomiting and retching and migraine and chills and severe fatigue.- Lasting 12 hours.   Treated with compazine and zofran po and imetrex.    Left arm ache for 3 days post injection and couple days with severe fatigue, headaches.  Remain intermittent itching of extremities with cracked dry skin hands.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: No adverse reaction.  Vaccine temperature excursion.  Vaccine was kept at a frozen temperature, not refrigerated temperature upon receipt of shipment.
Age: 8.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product preparation issue
Clinical narrative: Patient received Covid booster dose of Pfizer 5-11 that was under diluted. Per guidelines no repeat dose administered. Mother denies adverse events after administration.
Age: 12.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: No adverse reaction.  Vaccine temperature excursion.  Vaccine was kept at a frozen temperature, not refrigerated temperature upon receipt of shipment.
Age: 5.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product preparation issue
Clinical narrative: Patient received under-diluted dose of Pfizer 5-11 vaccine. No signs of adverse side effects noted at this time.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Heart rate increased, Mechanical urticaria, Rash, Rash pruritic, Urticaria
Clinical narrative: 4/30/2021: Received second Moderna vaccine dose. 5/11/2021: Broke out in itchy rash all over body.  Ithchy welts appear in response to rubbing or scratching. 5/13/2021: Telemedicine consult, with photographs of rash.  Diagnosed "Dermatographic urticaria". Telemedicine visit summary reports Procedure codes. 5/14/2021: Began taking daily Loratadine for treatment. 5/26/2021: Itchy rash issue resolved.  Note: Health tracker records indicate elevated resting heartrate for 16 days.  5/11 - 5/26.  Then resting heartrate returned to baseline.  Similar reaction after Dose 3. 12/04/2021: Received Moderna Dose 3 (Lot 018FZ1A). 12/13/2021: Again, itching and rash started.  Same dermatographic urticaria symptoms as after Dose 2. Took 10mg Loratadine daily. 12/28/2021: Itchy skin reaction ongoing.  Elevated resting heartrate indicated by health tracker. 02/03/2022: Skin reactivity finally stopped.  Health tracker resting heartrate returned to pre-Dose-3 levels.  4/8/2022: I had submitted reports through the text message vaccine follow up system, V-safe. A representative from V-Safe called me on 4/8/2022, and encouraged me to report my experience through VAERS.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus (in both ears) which began a couple days after the fourth shot.
Age: 6.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product preparation issue
Clinical narrative: Patient received under diluted dose of vaccine. No adverse side effects reported per mother at this time.
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Discomfort, Injection site rash, Irritability, Pruritus
Clinical narrative: Patient came to the pharmacy with a rash (roughly baseball sized) around the injection site of her Shingrix vaccine, she reported no other symptoms and only reported mild discomfort/itchiness. Given the delayed onset and degree of symptoms I directed her to purchase and take some Benadryl for the itchiness and irritability. I also informed her that if the rash worsens or new symptoms develop to contact a doctor immediately.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Ear discomfort
Clinical narrative: popping sound in ear
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Conjunctival haemorrhage
Clinical narrative: Left eye subconjunctival hemorrhage.
Age: 69.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Cellulitis, Chemotherapy, Computerised tomogram neck, Deformity
Clinical narrative: Hospitalized (5.24.22);  COVID-19 positive (5.24.22);  Fully vaccinated PLUS booster BRIEF OVERVIEW: Hematologist/Oncologist: MD Primary Care Physician at Discharge: DO Admission Date: 5/24/2022 Discharge Date: 06/06/2022 DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Neutropenic fever (HCC)  COVID-19  HOSPITAL COURSE: The patient is a 69-year-old male with past medical history significant for squamous cell carcinoma of the right mandible and right posterior lateral tongue status post surgical resection.  Patient is currently receiving weekly cisplatin and concurrent radiation.The patient was recently admitted 5/3 -5/6/22 with sepsis secondary to right facial and neck cellulitis. Patient was seen in the office on the day of admission ( 5/24) for his weekly cisplatin and found to be febrile and tachycardic and sent to the emergency department for further evaluation.  In the emergency department he tested positive for Covid-19, patient was started on cefepime and vancomycin with Infectious workup.  CT neck 5/24/22 - interval decrease in size of several heterogenous masses right lateral neck suggesting favorable treatment response.  Some of these masses could represent superinfection which is improving.  No new or enlarging neck masses.  Persistent prominent right facial swelling and edema suggestive of cellulitis. ENT assessed the patient and did a  flexible laryngoscopy,  no  airway obstruction was noted, but he was noted to have a right-sided asymmetry in hypopharynx and lateral pharyngeal wall. Steroids were started to help with swelling.  They recommended  moisturized air and mucolytics. ID was asked to see and were concerned some of the erythema was radiation induced. He had repeat fevers and AMS. He was changed to merrem and neurology was asked to see for AMS. EEG was done showing encephalopathy. Neurology initially felt he needed a LP as part of the work up for encephalitis. But that resolved and the concern for encephalitis was resolved. Antibiotics were DC'd on 6/4. He was stable for DC on 6/6. He had RT prior to DC and was sent on a steroid taper of 4 Mg TID x3 days, 4 MG BID x 3 days and 4 mg daily x 3 days, then 2 mg daily x 3 days and stop. He has follow-up as listed above.
Age: 69.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dizziness, Electroencephalogram abnormal, Encephalopathy, Face oedema, Febrile neutropenia
Clinical narrative: Hospitalized (5.24.22);  COVID-19 positive (5.24.22);  Fully vaccinated PLUS booster BRIEF OVERVIEW: Hematologist/Oncologist: MD Primary Care Physician at Discharge: DO Admission Date: 5/24/2022 Discharge Date: 06/06/2022 DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Neutropenic fever (HCC)  COVID-19  HOSPITAL COURSE: The patient is a 69-year-old male with past medical history significant for squamous cell carcinoma of the right mandible and right posterior lateral tongue status post surgical resection.  Patient is currently receiving weekly cisplatin and concurrent radiation.The patient was recently admitted 5/3 -5/6/22 with sepsis secondary to right facial and neck cellulitis. Patient was seen in the office on the day of admission ( 5/24) for his weekly cisplatin and found to be febrile and tachycardic and sent to the emergency department for further evaluation.  In the emergency department he tested positive for Covid-19, patient was started on cefepime and vancomycin with Infectious workup.  CT neck 5/24/22 - interval decrease in size of several heterogenous masses right lateral neck suggesting favorable treatment response.  Some of these masses could represent superinfection which is improving.  No new or enlarging neck masses.  Persistent prominent right facial swelling and edema suggestive of cellulitis. ENT assessed the patient and did a  flexible laryngoscopy,  no  airway obstruction was noted, but he was noted to have a right-sided asymmetry in hypopharynx and lateral pharyngeal wall. Steroids were started to help with swelling.  They recommended  moisturized air and mucolytics. ID was asked to see and were concerned some of the erythema was radiation induced. He had repeat fevers and AMS. He was changed to merrem and neurology was asked to see for AMS. EEG was done showing encephalopathy. Neurology initially felt he needed a LP as part of the work up for encephalitis. But that resolved and the concern for encephalitis was resolved. Antibiotics were DC'd on 6/4. He was stable for DC on 6/6. He had RT prior to DC and was sent on a steroid taper of 4 Mg TID x3 days, 4 MG BID x 3 days and 4 mg daily x 3 days, then 2 mg daily x 3 days and stop. He has follow-up as listed above.
Age: 69.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Gastrostomy, Hypotension, Infection, Laryngoscopy abnormal, Mental status changes
Clinical narrative: Hospitalized (5.24.22);  COVID-19 positive (5.24.22);  Fully vaccinated PLUS booster BRIEF OVERVIEW: Hematologist/Oncologist: MD Primary Care Physician at Discharge: DO Admission Date: 5/24/2022 Discharge Date: 06/06/2022 DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Neutropenic fever (HCC)  COVID-19  HOSPITAL COURSE: The patient is a 69-year-old male with past medical history significant for squamous cell carcinoma of the right mandible and right posterior lateral tongue status post surgical resection.  Patient is currently receiving weekly cisplatin and concurrent radiation.The patient was recently admitted 5/3 -5/6/22 with sepsis secondary to right facial and neck cellulitis. Patient was seen in the office on the day of admission ( 5/24) for his weekly cisplatin and found to be febrile and tachycardic and sent to the emergency department for further evaluation.  In the emergency department he tested positive for Covid-19, patient was started on cefepime and vancomycin with Infectious workup.  CT neck 5/24/22 - interval decrease in size of several heterogenous masses right lateral neck suggesting favorable treatment response.  Some of these masses could represent superinfection which is improving.  No new or enlarging neck masses.  Persistent prominent right facial swelling and edema suggestive of cellulitis. ENT assessed the patient and did a  flexible laryngoscopy,  no  airway obstruction was noted, but he was noted to have a right-sided asymmetry in hypopharynx and lateral pharyngeal wall. Steroids were started to help with swelling.  They recommended  moisturized air and mucolytics. ID was asked to see and were concerned some of the erythema was radiation induced. He had repeat fevers and AMS. He was changed to merrem and neurology was asked to see for AMS. EEG was done showing encephalopathy. Neurology initially felt he needed a LP as part of the work up for encephalitis. But that resolved and the concern for encephalitis was resolved. Antibiotics were DC'd on 6/4. He was stable for DC on 6/6. He had RT prior to DC and was sent on a steroid taper of 4 Mg TID x3 days, 4 MG BID x 3 days and 4 mg daily x 3 days, then 2 mg daily x 3 days and stop. He has follow-up as listed above.
Age: 69.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Neck mass, Post procedural complication, Pyrexia, Radiotherapy, SARS-CoV-2 test positive
Clinical narrative: Hospitalized (5.24.22);  COVID-19 positive (5.24.22);  Fully vaccinated PLUS booster BRIEF OVERVIEW: Hematologist/Oncologist: MD Primary Care Physician at Discharge: DO Admission Date: 5/24/2022 Discharge Date: 06/06/2022 DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Neutropenic fever (HCC)  COVID-19  HOSPITAL COURSE: The patient is a 69-year-old male with past medical history significant for squamous cell carcinoma of the right mandible and right posterior lateral tongue status post surgical resection.  Patient is currently receiving weekly cisplatin and concurrent radiation.The patient was recently admitted 5/3 -5/6/22 with sepsis secondary to right facial and neck cellulitis. Patient was seen in the office on the day of admission ( 5/24) for his weekly cisplatin and found to be febrile and tachycardic and sent to the emergency department for further evaluation.  In the emergency department he tested positive for Covid-19, patient was started on cefepime and vancomycin with Infectious workup.  CT neck 5/24/22 - interval decrease in size of several heterogenous masses right lateral neck suggesting favorable treatment response.  Some of these masses could represent superinfection which is improving.  No new or enlarging neck masses.  Persistent prominent right facial swelling and edema suggestive of cellulitis. ENT assessed the patient and did a  flexible laryngoscopy,  no  airway obstruction was noted, but he was noted to have a right-sided asymmetry in hypopharynx and lateral pharyngeal wall. Steroids were started to help with swelling.  They recommended  moisturized air and mucolytics. ID was asked to see and were concerned some of the erythema was radiation induced. He had repeat fevers and AMS. He was changed to merrem and neurology was asked to see for AMS. EEG was done showing encephalopathy. Neurology initially felt he needed a LP as part of the work up for encephalitis. But that resolved and the concern for encephalitis was resolved. Antibiotics were DC'd on 6/4. He was stable for DC on 6/6. He had RT prior to DC and was sent on a steroid taper of 4 Mg TID x3 days, 4 MG BID x 3 days and 4 mg daily x 3 days, then 2 mg daily x 3 days and stop. He has follow-up as listed above.
Age: 69.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Secretion discharge, Sepsis, Superinfection, Swelling face, Tachycardia
Clinical narrative: Hospitalized (5.24.22);  COVID-19 positive (5.24.22);  Fully vaccinated PLUS booster BRIEF OVERVIEW: Hematologist/Oncologist: MD Primary Care Physician at Discharge: DO Admission Date: 5/24/2022 Discharge Date: 06/06/2022 DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Neutropenic fever (HCC)  COVID-19  HOSPITAL COURSE: The patient is a 69-year-old male with past medical history significant for squamous cell carcinoma of the right mandible and right posterior lateral tongue status post surgical resection.  Patient is currently receiving weekly cisplatin and concurrent radiation.The patient was recently admitted 5/3 -5/6/22 with sepsis secondary to right facial and neck cellulitis. Patient was seen in the office on the day of admission ( 5/24) for his weekly cisplatin and found to be febrile and tachycardic and sent to the emergency department for further evaluation.  In the emergency department he tested positive for Covid-19, patient was started on cefepime and vancomycin with Infectious workup.  CT neck 5/24/22 - interval decrease in size of several heterogenous masses right lateral neck suggesting favorable treatment response.  Some of these masses could represent superinfection which is improving.  No new or enlarging neck masses.  Persistent prominent right facial swelling and edema suggestive of cellulitis. ENT assessed the patient and did a  flexible laryngoscopy,  no  airway obstruction was noted, but he was noted to have a right-sided asymmetry in hypopharynx and lateral pharyngeal wall. Steroids were started to help with swelling.  They recommended  moisturized air and mucolytics. ID was asked to see and were concerned some of the erythema was radiation induced. He had repeat fevers and AMS. He was changed to merrem and neurology was asked to see for AMS. EEG was done showing encephalopathy. Neurology initially felt he needed a LP as part of the work up for encephalitis. But that resolved and the concern for encephalitis was resolved. Antibiotics were DC'd on 6/4. He was stable for DC on 6/6. He had RT prior to DC and was sent on a steroid taper of 4 Mg TID x3 days, 4 MG BID x 3 days and 4 mg daily x 3 days, then 2 mg daily x 3 days and stop. He has follow-up as listed above.
Age: 9.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product preparation issue
Clinical narrative: Patient received under diluted dose of Pfizer 5-11 vaccine. No adverse side effects reported at this time.
Age: 5.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product preparation issue
Clinical narrative: Patient received under diluted dose of Pfizer 5-11 vaccine. No adverse effect reported at this time.
Age: 8.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Product preparation issue, Vomiting
Clinical narrative: Patient received under diluted dose of 5-11 pfizer vaccine. Had  nausea and vomiting for one day and severe headache for 2 days but symptoms had resolved when parent notified on 6/1/2022.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Immunodeficiency, Underdose
Clinical narrative: Patient was given incorrect dose of Moderna. She is immunocompromised and needed to receive a 3rd full dose to complete her primary vaccination series but instead was given 0.25mL as a booster
Age: 10.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product preparation issue
Clinical narrative: Patient received under diluted dose of vaccine. No adverse effects noted at this time.
Age: 7.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect dose administered, No adverse event, Product preparation error
Clinical narrative: Patient received under diluted dose of covid vaccine. NO adverse effects noted by parent at this time.
Age: 8.0
Sex: U
Vaccine: COVID19
Symptoms: Product preparation issue, Vomiting
Clinical narrative: Patient received under diluted dose of pfizer 5-11 vaccine. Had vomiting after vaccine and received Zofran.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Blindness, Body temperature increased, Eye disorder, Feeling abnormal
Clinical narrative: Weird feeling came over me. Check Blood pressure it was good. Went to an appt with mother was told temp at 102.4 this was 2 1/2 hours after shot. Also had vision loss by 25% for 2 days. Weird feeling stayed with me for as ling as eyes were acting up.
Sex: F
Vaccine: COVID19
Symptoms: Bone pain, Mobility decreased, Pain
Clinical narrative: Received Prolia 02/04/2021. Pain gradually came on worse and worse Primary care Doctor prescribed 800mg of ibuprofen every 6 hrs to releive my pain - not much effect. My entire skeleton is a mass of pain and I noticed the pain (3/7/21) more severely and it was paralyzing. Ever since the pain has not left me. On Jan 18, received Covid 19 vaccine On Feb 4, received Prolia injection On Feb 9, received Covid 19 2nd vaccine To be fair I mention this in case it may have to do with the pain I', having, which his still severe
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired vaccine given, no tx, no outcome
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired vaccine given, no tx, none
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired vaccine given, no tx, no outcome
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Wheelchair user
Clinical narrative: put on a walker/wheelchair/I am struggling significantly on disability; now I need a walker, wheel chair, spending over 13 months; I went from very healthy to not good at all; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 50-year-old female patient received BNT162b2 (BNT162B2), on 13Apr2021 as dose 2, single (Lot number: ER8731) at the age of 49 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose:1, Manufacturer Unknown), for COVID-19 Immunization. The following information was reported: MALAISE (disability) with onset Apr2021, outcome "unknown", described as "I went from very healthy to not good at all"; WHEELCHAIR USER (hospitalization, disability) with onset Apr2021, outcome "not recovered", described as "put on a walker/wheelchair/I am struggling significantly on disability; now I need a walker, wheel chair, spending over 13 months".  Clinical information: Patient had a very bad reaction and still suffering from more than 13 months now. Patient have connected with many others who were suffering and have got connected with two people specifically who had the same batch number patient had, which was concerning for me personally. So, wanted to alert you also. patient do not think you have updated all of the issues that he is having. So, not sure what was reported back whenever he called and sent in that report a long time ago. But still suffering and getting new diagnosis on a regular basis. When clarified if the other two patients also experienced the same experiences as that of the consumer, Consumer stated, "Well, not exactly the same reaction. One died, a 16-year-old boy died and then another woman. she is younger than patient. She did get IVIG (treatment) right out of the kit, she got treatment on adverse like reaction to a vaccine (Pfizer COVID-19 Vaccine). She is doing much better than I am. You know, one passed away. patient struggling significantly on disability and I was previously very active. I was a long distance biker, I am a triathlete and now I need a walker, wheel chair, spending over 13 months. So, I just want to make sure that part is noted and I mean I feel like that there should be a follow-up too from Pfizer to the people who had adverse events. So, there is more study being done about (incomplete sentence)."  No follow-up attempts are possible. No further information is expected.
Age: 63.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Insomnia, Pain in extremity
Clinical narrative: Hurt from the shot and slowly got sore more and more as time goes by
Age: 63.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pain
Clinical narrative: Hurt from the shot and slowly got sore more and more as time goes by
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Abdominal discomfort
Clinical narrative: got sick with covid twice within 1 month and my efficacy rate on the 4th shot was only 26%; got sick with covid twice within 1 month and my efficacy rate on the 4th shot was only 26%; had a "Pityriasis rosea reaction after his 4th shot"; that mRNA vaccine don't work to him, had a reaction problem to mRNA vaccine on the 4th shot; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A male patient received BNT162b2 (COMIRNATY), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Hpv vaccine (got his first shot of HPV vaccine at 65 year old.), when the patient was 65 years old, for Immunization; Bnt162b2 (Dose: 3, I got sick with COVID twice within 1 month), for COVID-19 Immunization, reaction(s): "COVID"; Bnt162b2 (Dose: 2, I got sick with COVID twice within 1 month), for COVID-19 Immunization, reaction(s): "COVID"; Bnt162b2 (Dose: 1, I got sick with COVID twice within 1 month), for COVID-19 Immunization, reaction(s): "COVID-19".  The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "got sick with covid twice within 1 month and my efficacy rate on the 4th shot was only 26%"; PITYRIASIS ROSEA (non-serious), outcome "unknown", described as "had a "Pityriasis rosea reaction after his 4th shot""; IMMUNISATION REACTION (non-serious), outcome "unknown", described as "that mRNA vaccine don't work to him, had a reaction   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Drug ineffective, Immunisation reaction, Pityriasis rosea, Suspected COVID-19
Clinical narrative: got sick with covid twice within 1 month and my efficacy rate on the 4th shot was only 26%; got sick with covid twice within 1 month and my efficacy rate on the 4th shot was only 26%; had a "Pityriasis rosea reaction after his 4th shot"; that mRNA vaccine don't work to him, had a reaction problem to mRNA vaccine on the 4th shot; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A male patient received BNT162b2 (COMIRNATY), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Hpv vaccine (got his first shot of HPV vaccine at 65 year old.), when the patient was 65 years old, for Immunization; Bnt162b2 (Dose: 3, I got sick with COVID twice within 1 month), for COVID-19 Immunization, reaction(s): "COVID"; Bnt162b2 (Dose: 2, I got sick with COVID twice within 1 month), for COVID-19 Immunization, reaction(s): "COVID"; Bnt162b2 (Dose: 1, I got sick with COVID twice within 1 month), for COVID-19 Immunization, reaction(s): "COVID-19".  The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "got sick with covid twice within 1 month and my efficacy rate on the 4th shot was only 26%"; PITYRIASIS ROSEA (non-serious), outcome "unknown", described as "had a "Pityriasis rosea reaction after his 4th shot""; IMMUNISATION REACTION (non-serious), outcome "unknown", described as "that mRNA vaccine don't work to him, had a reaction   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: got sick with covid twice within 1 month and my efficacy rate on the 4th shot was only 26%; got sick with covid twice within 1 month and my efficacy rate on the 4th shot was only 26%; had a "Pityriasis rosea reaction after his 4th shot"; that mRNA vaccine don't work to him, had a reaction problem to mRNA vaccine on the 4th shot; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A male patient received BNT162b2 (COMIRNATY), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Hpv vaccine (got his first shot of HPV vaccine at 65 year old.), when the patient was 65 years old, for Immunization; Bnt162b2 (Dose: 3, I got sick with COVID twice within 1 month), for COVID-19 Immunization, reaction(s): "COVID"; Bnt162b2 (Dose: 2, I got sick with COVID twice within 1 month), for COVID-19 Immunization, reaction(s): "COVID"; Bnt162b2 (Dose: 1, I got sick with COVID twice within 1 month), for COVID-19 Immunization, reaction(s): "COVID-19".  The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "got sick with covid twice within 1 month and my efficacy rate on the 4th shot was only 26%"; PITYRIASIS ROSEA (non-serious), outcome "unknown", described as "had a "Pityriasis rosea reaction after his 4th shot""; IMMUNISATION REACTION (non-serious), outcome "unknown", described as "that mRNA vaccine don't work to him, had a reaction   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash, Rash erythematous, Rash pruritic
Clinical narrative: I woke up with the diffuse erythematous rash; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 64-year-old female patient received BNT162b2 (BNT162B2), on 25May2022 as dose number unknown, single (Lot number: FK9894) at the age of 64 years, in right arm for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: RASH ERYTHEMATOUS (non-serious) with onset May2022, outcome "unknown", described as "I woke up with the diffuse erythematous rash". Therapeutic measures were taken as a result of rash erythematous.  Additional information: The patient did not had any vaccination 4 weeks prior to BNT162B2. The patient was treated with mometasone ointment, Benadryl and metrol dose pack.
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash erythematous
Clinical narrative: I woke up with the diffuse erythematous rash; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 64-year-old female patient received BNT162b2 (BNT162B2), on 25May2022 as dose number unknown, single (Lot number: FK9894) at the age of 64 years, in right arm for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: RASH ERYTHEMATOUS (non-serious) with onset May2022, outcome "unknown", described as "I woke up with the diffuse erythematous rash". Therapeutic measures were taken as a result of rash erythematous.  Additional information: The patient did not had any vaccination 4 weeks prior to BNT162B2. The patient was treated with mometasone ointment, Benadryl and metrol dose pack.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthma, Chest discomfort, Dyspnoea
Clinical narrative: persistent cough; Asthma exacerbation; chest tightness; difficulty breathing; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 37-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 28May2022 at 11:00 as dose 4 (booster), single (Lot number: FJ4991) at the age of 37 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Mild asthma" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose: 1, Manufacturer unknown), for Covid-19 Immunization; Covid-19 vaccine (Dose: 2, Manufacturer unknown), for Covid-19 Immunization; Covid-19 vaccine (Dose: 3, Manufacturer unknown), for Covid-19 Immunization. The following information was reported: ASTHMA (medically significant) with onset 28May2022 at 19:00, outcome "recovering", described as "Asthma exacerbation"; CHEST DISCOMFORT (medically significant) with onset 28May2022 at 19:00, outcome "recovering", described as "chest tightness"; DYSPNOEA (medically significant) with onset 28May2022 at 19:00, outcome "recovering", described as "difficulty breathing"; COUGH (medically significant) with onset 28May2022 at 19:00, outcome "recovering", described as "persistent cough". The events "persistent cough", "asthma exacerbation", "chest tightness" and "difficulty breathing" required emergency room visit. Therapeutic measures were taken as a result of cough, asthma, chest discomfort, dyspnoea.  Clinical course: The patient had no known allergies. She did not receive other vaccine in four weeks. She did not have covid prior vaccination and did not tested for covid post vaccination. The patient was treated with dexamethasone.  Follow-up attempts are completed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthma, Chest discomfort, Cough, Dyspnoea
Clinical narrative: persistent cough; Asthma exacerbation; chest tightness; difficulty breathing; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 37-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 28May2022 at 11:00 as dose 4 (booster), single (Lot number: FJ4991) at the age of 37 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Mild asthma" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose: 1, Manufacturer unknown), for Covid-19 Immunization; Covid-19 vaccine (Dose: 2, Manufacturer unknown), for Covid-19 Immunization; Covid-19 vaccine (Dose: 3, Manufacturer unknown), for Covid-19 Immunization. The following information was reported: ASTHMA (medically significant) with onset 28May2022 at 19:00, outcome "recovering", described as "Asthma exacerbation"; CHEST DISCOMFORT (medically significant) with onset 28May2022 at 19:00, outcome "recovering", described as "chest tightness"; DYSPNOEA (medically significant) with onset 28May2022 at 19:00, outcome "recovering", described as "difficulty breathing"; COUGH (medically significant) with onset 28May2022 at 19:00, outcome "recovering", described as "persistent cough". The events "persistent cough", "asthma exacerbation", "chest tightness" and "difficulty breathing" required emergency room visit. Therapeutic measures were taken as a result of cough, asthma, chest discomfort, dyspnoea.  Clinical course: The patient had no known allergies. She did not receive other vaccine in four weeks. She did not have covid prior vaccination and did not tested for covid post vaccination. The patient was treated with dexamethasone.  Follow-up attempts are completed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vaccination site erythema, Vaccination site pruritus
Clinical narrative: This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient. A 58-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 31May2022 at 12:45 as dose 4 (booster), single (Lot number: FJ4989) at the age of 58 years, in left arm for covid-19 immunization. The patient's relevant medical history included: "Hashimoto's" (unspecified if ongoing), notes: Hashimoto's; "Known allergies: cat dander" (unspecified if ongoing), notes: Known allergies: cat dander. Concomitant medication(s) included: ARMOUR THYROID. Past drug history included: Erythromycin, reaction(s): "Known allergies: Erythromycin", notes: Known allergies: Erythromycin; Cinnamon oil, reaction(s): "Known allergies: Cinnamon oil", notes: Known allergies: Cinnamon oil. Vaccination history included: Covid-19 vaccine (Dose 1, Manufacturer unknown), for COVID-19 immunization; Covid-19 vaccine (Dose 2, Manufacturer unknown), for COVID-19 immunization; Covid-19 vaccine (Dose 3, Manufacturer unknown), for COVID-19 immunization. The following information was reported: VACCINATION SITE PRURITUS (non-serious), VACCINATION SITE ERYTHEMA (non-serious) all with onset 02Jun2022 at 18:00, outcome "not recovered" and all described as "Red, itchy circle around vaccine site.". Therapeutic measures were not taken as a result of vaccination site pruritus, vaccination site erythema. Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was neither diagnosed with COVID-19 Prior to vaccination, nor been tested for COVID-19 Since the vaccination.
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Body temperature, Cough, Malaise, Pyrexia
Clinical narrative: Patient received 1st dose on 15-Apr-2021 and 2nd dose on 21-May-2021 which was beyond 25-35 days time interval; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 1st dose on 15-Apr-2021 and 2nd dose on 21-May-2021 which was beyond 25-35 days time interval) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Vitamin D deficiency and Allergy NOS (No known drug allergy).   On 15-Apr-2021 at 6:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-May-2021 at 6:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-May-2021 at 6:00 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 1st dose on 15-Apr-2021 and 2nd dose on 21-May-2021 which was beyond 25-35 days time interval). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 1st dose on 15-Apr-2021 and 2nd dose on 21-May-2021 which was beyond 25-35 days time interval) outcome was unknown.            No concomitant medications were reported. No treatment information were reported.   This case was linked to MOD-2022-580179 (Patient Link).
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Patient received 1st dose on 15-Apr-2021 and 2nd dose on 21-May-2021 which was beyond 25-35 days time interval; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 1st dose on 15-Apr-2021 and 2nd dose on 21-May-2021 which was beyond 25-35 days time interval) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Vitamin D deficiency and Allergy NOS (No known drug allergy).   On 15-Apr-2021 at 6:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-May-2021 at 6:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-May-2021 at 6:00 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 1st dose on 15-Apr-2021 and 2nd dose on 21-May-2021 which was beyond 25-35 days time interval). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 1st dose on 15-Apr-2021 and 2nd dose on 21-May-2021 which was beyond 25-35 days time interval) outcome was unknown.            No concomitant medications were reported. No treatment information were reported.   This case was linked to MOD-2022-580179 (Patient Link).
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Biopsy, Computerised tomogram, Fatigue, Lymphadenopathy, Swelling
Clinical narrative: Swollen Glands on both side of neck /More Swollen glands on the left side of neck /Biopsy revealed abnormal looking glands in neck  /CT Scan Confirmed larger than normal numerous ones/Glands on both side of neck looked like Mononucleosis; Felt very tired after first Booster; Swollen in neck after first booster; This spontaneous case was reported by a patient and describes the occurrence of SWELLING (Swollen in neck after first booster), LYMPHADENOPATHY (Swollen Glands on both side of neck /More Swollen glands on the left side of neck /Biopsy revealed abnormal looking glands in neck  /CT Scan Confirmed larger than normal numerous ones/Glands on both side of neck looked like Mononucleosis) and FATIGUE (Felt very tired after first Booster) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. NDPE 939903, 032M20A and 031L20A) for COVID-19 vaccination.     The patient's past medical history included Tongue dry in 1999. Concurrent medical conditions included Atrial fibrillation, Blood pressure high and High cholesterol.   On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2021, the patient experienced SWELLING (Swollen in neck after first booster). On 26-Oct-2021, the patient experienced LYMPHADENOPATHY (Swollen Glands on both side of neck /More Swollen glands on the left side of neck /Biopsy revealed abnormal looking glands in neck  /CT Scan Confirmed larger than normal numerous ones/Glands on both side of neck looked like Mononucleosis) and FATIGUE (Felt very tired after first Booster). At the time of the report, SWELLING (Swollen in neck after first booster), LYMPHADENOPATHY (Swollen Glands on both side of neck /More Swollen glands on the left side of neck /Biopsy revealed abnormal looking glands in neck  /CT Scan Confirmed larger than normal numerous ones/Glands on both side of neck looked like Mononucleosis) and FATIGUE (Felt very tired after first Booster) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Biopsy: Biopsy ruled out cancer after first booster. In 2021, Computerised tomogram: CT Scan Confirmed larger than normal numerous ones after first booster. In 2021, Ultrasound scan: Ultrasound revealed level 4 carotid canal after first booster.         The patient did not have her medication list on her. No concomitant medication were reported. No treatment information were provided.   This case was linked to MOD-2022-581493.   Most recent FOLLOW-UP information incorporated above includes: On 01-Jun-2022: Follow-up contains no new information.